0.18% COL-118 facial gel (1.8 mg brimonidine)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Erythematous Rosacea

Drug Information

Target Indication

Erythematous Rosacea

Clinical Trial

Last updated: 1/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA2/20/2014

Mirvaso

Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.

Drug Science

Mechanism of action & safety profile

Developer

GALDY

Galderma Group AG/ADR

Related Pipeline

Actinic Keratoses

Acne

Glabellar Lines

Actinic Keratoses

Moderate to Severe Glabellar Lines

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts